Autonomix Medical Inc (AMIX) Stock Price, Quote & News

Company Profile

Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company's technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related diso...

Industry: Medical Devices

Sector: Healthcare

Phone: 713 588 6150

Website: autonomix.com

Address:

21 Waterway Avenue, Suite 300, The Woodlands, United States

coolmate25 Apr. 8 at 5:54 PM

$AMIX See that's the problem with this stock since most of the people here are just day traders and some low life greedy SOB hourly traders , they don't let it breath . We really need some good professionals that can hold it for a while since this stock totally depends on investments .

0 · Reply

coolmate25 Apr. 8 at 3:12 PM

$AMIX

0 · Reply

coolmate25 Apr. 8 at 3:02 PM

$AMIX

0 · Reply

dwhall5056 Apr. 8 at 1:18 PM

$AMIX Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026 ... https://ir.autonomix.com/autonomix-medical-selected-for-featured-abstract-and-podium-presentation-of-long-term-pain-mitigation-in-pancreatic-cancer-at-sir-2026/

0 · Reply

coolmate25 Apr. 8 at 2:13 AM

$AMIX The next big upcoming news will be if they apply for De Novo application , they said in May I guess .

0 · Reply

SuperGreenToday Apr. 7 at 12:17 AM

$AMIX

0 · Reply

dwhall5056 Apr. 6 at 7:21 PM

$AMIX New SEC filing ... perhaps the company is getting things lined up to reward employees - hopefully good news is pending. (see the April 2nd filing at top of this page) ... https://ir.autonomix.com/sec-filings/

0 · Reply

coolmate25 Mar. 31 at 10:05 PM

$AMIX Right now, it seems elevated short interest with low short float availability so I will recommend BUY since there is a strong possibility of short squeeze.

1 · Reply

Righon23420 Mar. 31 at 9:52 PM

$AMIX does anyone know when they have to get above 1$ to stay listed? seems like its been a while.

1 · Reply

coolmate25 Mar. 30 at 6:15 PM

$AMIX Why is that pumping dumping sh-t ? Let it run people before any good news .

0 · Reply

Autonomix Medical Selected for Featured Abstract and Podium Presentation of Long-Term Pain Mitigation in Pancreatic Cancer at SIR 2026

Mar 11, 2026, 8:40 AM EDT - 4 weeks ago

Autonomix Medical to Present at LSI USA '26

Mar 5, 2026, 8:45 AM EST - 4 weeks ago

Autonomix Medical Selected for Best Innovation Competition at CRT 2026

Mar 4, 2026, 8:40 AM EST - 5 weeks ago

Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

Feb 25, 2026, 8:30 AM EST - 6 weeks ago

Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Publication Strategy and Scientific Validation

Feb 19, 2026, 8:30 AM EST - 6 weeks ago

Autonomix Medical Selected to Present New Long-Term Pain Mitigation Data in Pancreatic Cancer at SSO 2026 Annual Meeting in Podium Presentation

Jan 9, 2026, 8:45 AM EST - 3 months ago

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium

Dec 23, 2025, 8:45 AM EST - 3 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Highlights Expanding IP Portfolio and Multi-Indication Platform Strategy in Virtual Investor CEO Connect Segment

Dec 18, 2025, 8:30 AM EST - 3 months ago

Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Nov 26, 2025, 8:45 AM EST - 4 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

Oct 24, 2025, 9:00 AM EDT - 5 months ago

Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference

Oct 16, 2025, 9:15 AM EDT - 6 months ago

Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit

Oct 9, 2025, 8:45 AM EDT - 6 months ago

Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

Oct 2, 2025, 8:45 AM EDT - 6 months ago

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

Sep 29, 2025, 9:15 AM EDT - 6 months ago

Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System

Sep 4, 2025, 9:00 AM EDT - 7 months ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Sep 3, 2025, 8:30 AM EDT - 7 months ago

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

Sep 2, 2025, 8:30 AM EDT - 7 months ago

Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 18, 2025, 9:15 AM EDT - 8 months ago

Autonomix Medical, Inc. to Participate in Virtual Investor Webinar Hosted by Ladenburg Thalmann & Co. Inc.

Aug 15, 2025, 9:00 AM EDT - 8 months ago

Autonomix Medical, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 8:30 AM EDT - 8 months ago

Autonomix Medical, Inc. Finalizes Design Review of First-Ever Intravascular Nerve Sensing Catheter in Key Step Toward U.S. Clinical Studies

Jul 22, 2025, 8:45 AM EDT - 9 months ago

Autonomix Medical, Inc. Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 21, 2025, 8:45 AM EDT - 9 months ago

Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

Jun 30, 2025, 8:30 AM EDT - 10 months ago

Autonomix Medical, Inc. Treats First Patient in Follow-On Market Expansion Phase (“PoC 2”) of Proof-of-Concept Human Clinical Study

Jun 27, 2025, 8:00 AM EDT - 10 months ago

Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology

Jun 5, 2025, 8:45 AM EDT - 10 months ago

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

May 15, 2025, 8:30 AM EDT - 11 months ago

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

May 14, 2025, 9:20 AM EDT - 11 months ago

Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event

May 13, 2025, 9:20 AM EDT - 11 months ago

Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market

May 5, 2025, 8:30 AM EDT - 1 year ago

Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain

May 1, 2025, 9:25 AM EDT - 1 year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

Apr 30, 2025, 8:15 AM EDT - 1 year ago

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

Apr 24, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

Apr 17, 2025, 5:00 PM EDT - 1 year ago

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology

Apr 8, 2025, 8:15 AM EDT - 1 year ago

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Apr 3, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company's Proprietary Catheter-Based Technology

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation

Feb 20, 2025, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting

Feb 13, 2025, 8:00 AM EST - 1 year ago

Autonomix Medical, Inc. Reports Third Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

Jan 24, 2025, 8:45 AM EST - 1 year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment

Jan 17, 2025, 8:00 AM EST - 1 year ago

Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Jan 15, 2025, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Jan 13, 2025, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting

Dec 30, 2024, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology

Dec 5, 2024, 8:30 AM EST - 1 year ago

Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025

Nov 25, 2024, 4:00 PM EST - 1 year ago

Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option

Nov 22, 2024, 9:15 AM EST - 1 year ago

Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering

Nov 11, 2024, 8:00 AM EST - 1 year ago

Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update

coolmate25 Apr. 8 at 5:54 PM

0 · Reply

coolmate25 Apr. 8 at 3:12 PM

$AMIX

0 · Reply

coolmate25 Apr. 8 at 3:02 PM

$AMIX

0 · Reply

dwhall5056 Apr. 8 at 1:18 PM

0 · Reply

coolmate25 Apr. 8 at 2:13 AM

$AMIX The next big upcoming news will be if they apply for De Novo application , they said in May I guess .

0 · Reply

SuperGreenToday Apr. 7 at 12:17 AM

$AMIX

0 · Reply

dwhall5056 Apr. 6 at 7:21 PM

0 · Reply

coolmate25 Mar. 31 at 10:05 PM

$AMIX Right now, it seems elevated short interest with low short float availability so I will recommend BUY since there is a strong possibility of short squeeze.

1 · Reply

Righon23420 Mar. 31 at 9:52 PM

$AMIX does anyone know when they have to get above 1$ to stay listed? seems like its been a while.

1 · Reply

coolmate25 Mar. 30 at 6:15 PM

$AMIX Why is that pumping dumping sh-t ? Let it run people before any good news .

0 · Reply

dwhall5056 Mar. 29 at 7:43 PM

$AMIX ramblings ... looking at the recent past 6/27/25 the stock jumped 94% from 1.25 to 2.43 7/21/25 the stock jumped 72% from 1.53 to 2.64 11/17/25 the stock jumped 112% from 0.73 to 1.55 12/30/25 the stock jumped 66% from 0.54 to 0.90 I'm not going to miss the next big move when news hits.

0 · Reply

coolmate25 Mar. 25 at 5:09 PM

$AMIX Wtf is going on here ? Are we fckn kiddin here ? Are all these low lives trading or just fckn things up . Seriously?

1 · Reply

dwhall5056 Mar. 25 at 11:27 AM

$AMIX Does the company need FDA to sell to other countries? I'm thinking FDA is only needed for the USA. Perhaps not Canada and other countries. Perhaps they can Fast Track FDA since this technology is needed today.

1 · Reply

coolmate25 Mar. 24 at 8:02 PM

$AMIX Cheap people traded today.

0 · Reply

topstockalerts Mar. 24 at 11:49 AM

Pre Market Top Gainers PT2 $AMIX $BTM $MOVE.X $ZTEK $GLXG

0 · Reply

topstockalerts Mar. 24 at 11:04 AM

Pre Market Top Gainers PT2 $AMIX $BTM $MOVE.X $ZTEK $GLXG

0 · Reply

ClassifiedTrades Mar. 24 at 10:55 AM

Premarket Watchlist — Mar 24, 2026 $PAVS +66.7% Float 0.1M $UGRO +26.3% Float 0.7M $AMIX +16.6% Float 10.5M $SLGL +11.8% Float 0.8M $EDBL +11.0% Float 0.5M Bot-generated premarket watchlist (educational). Not financial advice.

0 · Reply

Ron_Burn Mar. 24 at 10:39 AM

$AMIX she's off to a good start

0 · Reply

PrnceMichael Mar. 23 at 12:18 PM

$ALBT Avalon subsidiary accepted into AMD AI developer program https://finance.yahoo.com/news/avalon-subsidiary-accepted-amd-ai-135721554.html $OCTO.X $AMIX

0 · Reply

GaryBx105 Mar. 22 at 7:24 PM

$AMIX imo the next major milestone, which will coincide with major stock pop followed by offering is completion of GLP study which is required to get FDA approval to begin clinical study. They began GLP study at end of Sept.

1 · Reply

VinWeezel Mar. 22 at 1:54 PM

$AMIX

0 · Reply

coolmate25 Mar. 20 at 6:05 PM

$AMIX This stock was on its way to moon a couple of days ago but one of the bigger investors messed it up for everyone after sale off, could be one of those institutional or insiders but I'm still committed till the end to stay strong.

0 · Reply

Market Cap	2.62M
Revenue (ttm)	0.00
Net Income (ttm)	-11.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	124,900
Avg Vol	171,740
Day's Range	N/A - N/A
Shares Out	6.91M
Stochastic %K	29%
Beta	-2.48
Analysts	Strong Sell
Price Target	$2.00